IOL Chemicals and Pharmaceuticals announced Q1FY24 results:
- Total income for Q1FY24 stood at Rs 570 crore at the same level of Rs 570 crore in Q1FY23
- EBITDA for Q1FY24 at Rs 80 crore as compared to Rs 61 crore in Q1FY23
- Net profit for Q1FY24 at Rs 46 crore as compared to Rs 35 crore in Q1FY23
Commenting on the performance, Vikas Gupta, Joint Managing Director, said, “We are pleased to report sustainable performance during Q1FY24, tackling present challenges while positioning ourselves for forthcoming opportunities. We are hopeful for an increased presence in regulatory markets as the Company got CEP for paracetamol. Additionally, with the commencement of the Acetic Anhydride plant, focus on improved efficiencies, product mix, and timely execution we are hopeful to generate strong cash flow”.